ACC.12 late-breaking trials include two imaging studies
“Issues like this are of enormous importance with respect to not only the efficiency with which patients are evaluated but also the cost and timeliness of their evaluation,” said ACC Chair Patrick T. O’Gara, MD, at a press briefing. “There has been much concern about the profligate use of CT and CT coronary angiography in various patients with either established or suspected coronary disease.”
Our editorial team will provide comprehensive coverage of the late-breaking clinical trials, which will include results on therapeutics, procedures and imaging as well as a large body of data from international studies. “This is an amazing lineup of late-breaking clinical trials that are aimed at broad and different ideas, patient care strategies and patient groups,” said ACC President David R. Holmes, Jr., MD.
The late-breaking trials and the date they will be presented are provided below.
Monday, March 26
ACRIN-PA trial: A multicenter, randomized controlled study of the American College of Radiology Imaging Network (ACRIN) to compare coronary CT angiography versus standard care of low-risk patients in emergency departments who present with potential ACS. In the study, patients were randomized to either a traditional “rule out” care group or a CT coronary angiography group to determine whether CT coronary angiography can be safely used to discharge low-risk patients to home from the emergency department.
Tuesday, March 27
ROMICAT II trial: A multicenter, randomized comparative effectiveness trial of cardiac CT compared with alternative triage strategies in patients who present with nondiagnostic chest pain in the emergency department. This study examines whether integrating cardiac CT improves the efficiency of the management of these patients.
More information about ACC.12 scientific sessions is available here.